Replies to post #202998 on Biotech Values

[mcbio]

ENTA's EDP-305 (FXR agonist) is not a bile acid, according to disclosures on recent CCs.

Great, thanks DD. So, potential to differentiate on the safety front from ICPT's OCA. And we'll see if the enhanced potency matters as well.

Would you say ENTA has played up more the potential safety advantages of EDP-305 or efficacy or both?